20 Future Norwegian HealthTech and MedTech Leaders

Nelson Advisors
52 minutes ago
15 min read

The Strategic Evolution of Norwegian HealthTech and MedTech: Analysis of 20 Emerging Leaders and the National Innovation Ecosystem

The Norwegian life sciences landscape is currently undergoing a systemic transition, evolving from a research-intensive academic environment into a globally integrated commercial powerhouse. This metamorphosis is facilitated by a unique confluence of high-trust public health data, a robust sovereign wealth environment and a maturing infrastructure of specialised clusters such as Norway Health Tech, the Oslo Cancer Cluster and Aleap. As the global healthcare market increasingly demands precision medicine, decentralised care models and AI-augmented diagnostics, Norway has positioned itself as a "forerunner" region.

This status is characterised by a "human scale" that allows for rapid testing and validation of sophisticated technologies within a public healthcare system, often referred to under the regional identity of "HealthFjords".

The following report provides an analysis of twenty future leaders within this sector, the technological breakthroughs they oversee and the second-order socio-economic impacts of their work on the global stage.

The Vanguard of Radiopharmaceuticals and Targeted Oncology

The most capital-intensive and scientifically rigorous segment of the Norwegian ecosystem is currently focused on targeted alpha therapies (TAT) and precision diagnostics. This sector leverages Norway’s historical expertise in nuclear science and oncology to address malignancies traditionally resistant to conventional treatments.

1. Jasper Kurth and Thor Medical: Scaling Alpha Emitter Production

Thor Medical ASA, directed by CEO Jasper Kurth, represents a critical shift in the global supply chain for modern oncology. Kurth, who possesses over fifteen years of leadership experience in the pharmaceutical and med-tech industries, including a significant tenure as General Manager of Radiology Nordics at Bayer, is spearheading the development of the AlphaOne commercial-scale plant at Herøya Industrial Park. The company focuses on the production of alpha-emitters derived from naturally occurring thorium, providing a reliable and environmentally friendly alternative to traditional nuclear reactor-based production.

The strategic significance of Thor Medical lies in its proprietary production process, AlphaCycle™, which requires no irradiation, thereby reducing regulatory hurdles and environmental impact. In early 2025, the company secured a NOK 90 Million loan facility from Innovation Norway, complementing a private placement and retail offering that raised approximately NOK 200 Million.

This funding ensures that the AlphaOne facility is fully capitalised through its 2026 production ramp-up.

Strategic Milestone	Metric / Detail	Timeline / Status	Source
Capital Raising	Private Placement and Retail Offering (NOK 173M initially)	December 2024	Various
Debt Financing	Innovation Norway Loan Facility (NOK 90M)	January 2025	Various
Operational Launch	Final Investment Decision (FID) for AlphaOne	March 2025	Various
Projected Output	25,000 patient doses annually	Within 5 years	Various
Market Valuation	Market capitalisation of approximately NOK 737.7M	December 31, 2024	Various

Kurth’s leadership is defined by a transition from pilot-stage validation to industrial-scale execution. The ability to produce medical isotopes at Herøya, where the pilot facility was ceremonially opened by the Norwegian Minister of Trade, positions Norway as a primary exporter in the radiopharmaceutical sector.

The high-quality production has already been verified by international customers, leading to multi-year sales agreements that secure nearly full capacity utilization for the AlphaOne plant before construction begins.

2. Esmaeil Dorraji and ImmunoQuest Therapeutics: Precision ADC Development

In the biopharmaceutical domain, Esmaeil Dorraji, founder and Chief Scientific Officer of ImmunoQuest Therapeutics, is advancing a novel class of Antibody-Drug Conjugates (ADCs). The company’s lead candidate, NAZ-001, is designed to target the p95HER2 protein—a truncated form of the HER2 receptor found exclusively in tumor cells. This selectivity is vital, as p95HER2 is associated with high rates of metastasis and resistance to existing HER2-targeted therapies such as trastuzumab.

Dorraji’s approach exemplifies the "precision" in precision medicine. By focusing on a biomarker absent in healthy tissue, ImmunoQuest reduces the systemic toxicity that often limits the efficacy of oncological drugs. The potential application of NAZ-001 extends beyond breast cancer to ovarian, lung, and colorectal cancers, indicating a broad total addressable market (TAM). The company recently joined the Oslo Cancer Cluster to leverage the ecosystem's connections with academic researchers and international investors.

3. Chee Yong and Elpis Biopharmaceuticals: Engineering Long-Lasting Cell Therapies

Elpis Biopharmaceuticals, co-founded by Co-CEO Chee Yong, is a clinical-stage cell therapy company that recently joined the Oslo Cancer Cluster to establish its European presence. While based in Boston and Singapore, the company’s expansion into Norway reflects the country’s growing leadership in advanced therapeutics and clinical trial infrastructure.

Under Yong’s leadership, Elpis is developing technologies that treat solid tumors by targeting multiple tumour pathways simultaneously. A core innovation in the Elpis pipeline is the ability to engineer immune cells that last longer in the patient's body without the harmful side effects typically associated with intensive cell therapies. The company's therapies are currently in clinical trials in China, with interim results anticipated by the end of 2025.

4. Anders M. Dale and Precision Health: Multimodal Clinical Decision Support

The integration of artificial intelligence into clinical workflows is spearheaded by Anders M. Dale, founder and CEO of Precision Health. Dale, an internationally recognized researcher with deep ties to both Norwegian and American academic institutions, focuses on developing multimodal tools for neurology, psychiatry, and oncology. Precision Health addresses diagnostic challenges such as Alzheimer’s disease, severe mental disorders, and prostate cancer.

Dale’s leadership emphasizes the necessity of being part of a collaborative ecosystem. By joining the Oslo Cancer Cluster, Precision Health has gained access to a network of university hospitals and global pharma partners, which Dale credits with helping the company avoid common developmental mistakes and fine-tuning its strategy. The company serves as a bridge between the clinical excellence of Norway and the commercial dynamism of the United States.

Innovations in Respiratory and Critical Care Monitoring

The Norwegian MedTech sector is dominated by hardware-software hybrids that automate vital sign monitoring, thereby reducing clinician fatigue and enhancing patient safety in acute settings.

5. Øystein Theodor Ødegaard-Olsen and Eupnea: Intelligent Respiratory Surveillance

Eupnea AS, co-founded by CEO Øystein Theodor Ødegaard-Olsen and Andreas Tunset, has emerged as a leader in wireless respiratory monitoring. The company’s core technology is a small, wireless sensor that transmits respiratory data via 5G networks to a Norwegian cloud-based data centre.

The clinical insight driving Eupnea is that respiratory rate is often the most reliable early indicator of physiological deterioration, yet it is the vital sign most frequently recorded manually or omitted during busy shifts.

Ødegaard-Olsen, who has a background in interdisciplinary group rehabilitation and clinical research at the University of Bergen, has overseen the validation of the sensor in prospective clinical studies. In 2025, Eupnea was recognised as a finalist for the Health Startup of the Year award, highlighting its potential to improve outcomes at institutions like Haraldsplass Deaconess Hospital.

Operational Feature	Specification / Impact	Source
Transmission Protocol	5G Network to Norwegian Cloud (no Bluetooth required)	Various
Clinical Validation	RespX accelerometer-based wireless sensor study	Various
Target Utility	Early detection of cardiac arrest and emergency admission	Various
Staff Impact	Reduces manual counting workload for nurses	Various

6. Trude Tingvoll and Respinor: Diaphragm Ultrasound for Ventilation Weaning

Respinor AS, led by CEO Trude Tingvoll, has reached significant international milestones with its RESPINOR DXT® technology. The device provides continuous, operator-independent ultrasound monitoring of the diaphragm to predict successful weaning from mechanical ventilation. This is critical for the 3.2 Million patients using respirators annually, as prolonged ventilation increases both costs and patient risk.

Tingvoll’s leadership has been instrumental in securing the FDA’s "Breakthrough Device" designation in late 2024 and the CE Mark under the EU MDR in August 2025. Furthermore, she participated in the NOME (Nordic Mentor Network for Entrepreneurship) U.S. delegation, which provided concrete investor leads and regulatory insights crucial for the company's expansion into the American market.

7. Fridtjof Heyerdahl and EpiGuard: High-End Isolation Systems

EpiGuard, founded in 2015 by Fridtjof Heyerdahl, MD, PhD, specialises in high-end medical isolation and transport systems. The company’s flagship product, the EpiShuttle, was developed to allow for the safe transport of patients with highly infectious diseases while protecting healthcare personnel.

Heyerdahl’s expertise in product development and manufacturing has positioned EpiGuard as a key player in global health security. The company is a portfolio business of Inven2, the technology transfer office for the University of Oslo and Oslo University Hospital. EpiGuard’s success demonstrates how Norwegian clinical innovation can be rapidly scaled to meet international demand during pandemics and other public health crises.

8. Nicolas Elvemo and GlucoSet: Continuous Glucose Control in the ICU

Nicolas Elvemo, co-founder of GlucoSet, focuses on metabolic monitoring in the Intensive Care Unit (ICU). GlucoSet develops tools for accurate continuous glucose control to reduce patient mortality and hospital costs associated with improper glucose management in critical care settings.

The company, which emerged as a spin-off from NTNU, utilizes advanced sensor technology to provide real-time data to clinicians. Elvemo’s leadership has been characterised by a commitment to rigorous technical validation, ensuring that the sensor can operate reliably in the high-stakes environment of an ICU.

Leadership in Women's Health and Reproductive Technology

FemTech is a burgeoning sub-sector in Norway, where entrepreneurs are addressing long-overlooked conditions such as maternal safety, endometriosis and fertility.

9. Hege Hansen and Induvita: Elevating Gynecological and Maternal Standards

Induvita AS, led by CEO Hege Hansen, was named the "Health Startup of the Year" (Årets helsegründer) for 2025. The company develops medical devices and training simulators designed to make vaginal examinations and gynaecological procedures more comfortable and safer for women.

Hansen’s strategy involves a comprehensive portfolio, including the Runa and Ayla training simulators, the Vega speculum (launching in 2026), and the Iola induction catheter. The Iola device is a balloon catheter designed to make labor induction more predictable and safer for both the clinician and the mother.

Hansen’s leadership is notable for its advocacy; she views the award not just as a business success, but as a signal that women's health is finally receiving the clinical and commercial attention it deserves.

10. Dilip K. Prasad and Spermotile: AI-Enhanced Male Fertility Solutions

Professor Dilip K. Prasad from UiT The Arctic University of Norway is the founder of Spermotile, a deep-tech MedTech company revolutionizing assisted reproduction technology (ART). Spermotile utilises AI-powered sperm selection technology to improve the success rates of In-Vitro Fertilisation (IVF).

Prasad has successfully raised $4 Million from high-profile sources, including the European Research Council (ERC) and the Research Council of Norway. The company is currently navigating the stringent regulatory pathways for CE marking and FDA clearance, a process required for deep-tech medical devices before commercial scaling. Prasad’s leadership is characterised by an interdisciplinary approach, combining advanced microscopy, fluid mechanics and bio-AI.

11. Kristian Larsen and Diagnostrix: Non-Invasive Diagnostics for Endometriosis

Diagnostrix is a joint venture between the Biolink Group (Norway) and Oratel Diagnostics (USA), directed by CEO Kristian Larsen. Larsen, a serial entrepreneur with over twenty years of experience in business development, has positioned Diagnostrix to solve the long-standing challenge of diagnosing endometriosis, which currently often requires invasive surgery.

The Diagnostrix solution uses color-detection technology for saliva testing, providing a low-cost and non-invasive alternative to traditional diagnostics. The team, which includes R&D Director Mariana T. Eiane, MD, and synthetic chemist Einar Bakstad, PhD, aims to make women's health diagnostics radically more accessible on a global scale.

Digital Health, AI and Remote Patient Management

Norway’s mature digital infrastructure provides a testing ground for AI-native startups that aim to automate clinical documentation and decentralise care follow-up.

12. Jorunn Thaulow and Medbric: Transforming Clinical Documentation with AI

Dr. Jorunn Thaulow, a physician and researcher, founded Medbric in late 2024 to address the dual challenges of antibiotic overuse and the administrative burden of clinical notes. Medbric’s ambient scribe solution, Aila, uses speech-to-note technology to generate personalised clinical documentation, allowing doctors to focus on patient interaction rather than their computer screens.

Within fifteen months of its launch, Medbric captured a market share of approximately 25-30% of all general practitioners in Norway and expanded into ten hospitals across the Helse Vest and Helse Midt-Norge regions. Thaulow’s leadership is defined by her "research-first" mentality, collaborating closely with the NorWAI research centre to ensure the AI agents are tailored to the Norwegian language and clinical requirements.

13. Anders Eikenes and Oivi: AI-Powered Diabetic Retinopathy Screening

Anders Eikenes, co-founder of Oivi and a former co-founder of Huddly, has pioneered an accessible AI-camera system for the early detection of diabetic eye disease. Eikenes’ vision is to provide an affordable, automated screening solution that can be deployed in primary care settings or community clinics, rather than requiring patients to visit specialised eye centres.

Eikenes brings a strong commercial and product-design background to the company. His leadership has focused on creating a "human-centred" device that is intuitive for non-specialist healthcare workers to operate, thereby democratising access to complex diagnostic imaging.

14. Espen Riskedal and AgeLabs: Predictive Models for Early Disease Detection

AgeLabs, founded by Espen Riskedal and Karl Trygve Kalleberg in 2017, utilizes machine learning to identify biological markers for early disease detection. Riskedal has led the company through various R&D projects with public institutions, focusing initially on age-related diseases and later expanding into the predictive modeling of COVID-19 severity.

Under Riskedal’s guidance, AgeLabs has secured nearly $1 Million in funding and earned nominations for Best Health Tech Startup at the Nordic Startup Awards. The company’s work represents the transition from reactive medicine to proactive, data-driven health interventions.

15. Marius Mathisen and Pletly: Harmonising Care for Vulnerable Populations

Marius Mathisen is the CEO of Pletly, a Norwegian-American healthtech firm that provides a connected care platform for individuals with cognitive challenges, such as dementia or autism. The platform bridges the communication gap between family members and professional caregivers, ensuring a single, accurate source of information for the "circle of care".

Mathisen’s leadership highlights the importance of empathy in HealthTech design. Founded by individuals with personal caregiving experience, Pletly has signed strategic agreements with special education academies and senior care providers like NewCourtland in Philadelphia, demonstrating the international scalability of the Norwegian "connected care" model.

Company	Focus Area	Key Leadership	Core Technology	Source
Medbric	Clinical AI	Jorunn Thaulow	Ambient Scribe (Aila)	Various
Oivi	Ophthalmology	Anders Eikenes	AI-integrated Camera	Various
AgeLabs	Predictive Health	Espen Riskedal	ML for Biomarkers	Various
Pletly	Connected Care	Marius Mathisen	Coordination Platform	Various

Neurotechnology and Robotic Rehabilitation

Advances in cybernetics and biofeedback are enabling new methods for treating neurological disorders and physical impairments that were previously considered untreatable.

16. Cathrine Ro Heuch and Nordic Brain Tech: Digital Biofeedback for Neurological Care

Cathrine Ro Heuch, CEO and co-founder of Nordic Brain Tech, leads a spin-off from NTNU and St. Olav's Hospital that aims to transform migraine care globally. The company’s flagship product, Cenli, is a digital biofeedback solution for home use that helps patients predict and prevent migraine attacks without the side effects of medication.

Heuch’s leadership is notable for its personal motivation, she has lived with migraines since her youth and her strategic utilisation of the Norwegian ecosystem. She has been named a "Rising Star" and appeared on the "40 under 40" list for leadership talent. Under her direction, Nordic Brain Tech successfully completed the NOME program and expanded its reach into the U.S. market through collaborations with the Mayo Clinic.

17. Saeid Hosseini and Vilje Bionics: Empowering Patients with Arm Exoskeletons

Saeid Hosseini, CEO and co-founder of Vilje Bionics, is overseeing the development of VilPower, a full-arm exoskeleton designed to restore movement for people with arm and hand paralysis. The system combines shoulder, elbow, wrist, and hand support in an innovative AI-driven device.

Hosseini, who moved to Norway in 2011 and co-founded the company at the age of 24, is motivated by the desire to use technology to bridge physical limitations. The company has raised $4 Million in funding and partnered with leading European medical institutions to validate the device's ability to mimic natural motion. Hosseini’s leadership represents the potential of impact-driven entrepreneurship to solve massive global health challenges affecting over 60 Million people.

Strategic Leadership in Biotech and Diagnostic Infrastructure

18. Jonas Hallén and Calluna Pharma: Tackling Fibrotic and Inflammatory Disease

Calluna Pharma, founded in 2024 through the merger of Oxitope and Arxx Therapeutics, is directed by Co-founder and Chief Medical Officer Jonas Hallén. The company focuses on developing therapeutics for inflammatory and fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF), where there is a significant unmet need for better-tolerated treatments.

Hallén, who brings drug development experience from Boehringer Ingelheim and Novartis, has overseen the advancement of CAL101, an S100A4 targeting monoclonal antibody currently in Phase II clinical trials. Calluna successfully raised €75 Million (approximately $81.7 Million) in a Series A round, one of the largest such rounds in the Norwegian biotech sector, to advance its pipeline. Hallén’s leadership emphasises the need for Norwegian startups to build international networks to access specialised manufacturing and clinical expertise.

19. Morten Isaksen and Bio-Me: Scaling Microbiome Diagnostics

Dr. Morten Isaksen, founder and CEO of Bio-Me, is developing a Precision Microbiome Profiling platform. This technology allows for the rapid, high-throughput analysis of the human gut microbiome, which is increasingly linked to diseases ranging from obesity to autoimmune disorders.

Isaksen has successfully utilised the Aleap Pre-Seed Fund to accelerate Bio-Me’s development program and market introduction. His leadership is central to Norway's efforts to become a hub for personalised nutrition and microbiome-based diagnostics, bridging the gap between molecular biology and clinical application.

20. Stig Morten Borch and SpinChip Diagnostics: Rapid Point-of-Care Testing

Stig Morten Borch, founder of SpinChip Diagnostics, is leading the development of a cutting-edge diagnostic platform designed for rapid and accurate point-of-care testing. SpinChip’s technology aims to provide lab-quality results within minutes, which is critical in emergency settings such as suspected cardiac events.

Borch’s leadership has focused on the engineering challenges of miniaturizing complex diagnostic procedures into a centrifugal microfluidic chip. The company represents the high-tech manufacturing capability that exists within the Norwegian MedTech cluster, where precision engineering meets clinical diagnostics.

Analysis of the Supporting Ecosystem: Clusters and Tech Transfer

The success of these twenty leaders is predicated on a highly coordinated support system that mitigates the risks associated with early-stage life science ventures.

The Role of Technology Transfer Offices (TTOs)

Inven2, the TTO for the University of Oslo and Oslo University Hospital, is a pivotal player in this ecosystem, managing a portfolio of approximately 50 companies with a combined value of around NOK 5 Billion. In 2024 alone, Inven2-backed startups raised NOK 670 Million in private capital.

Similarly, NTNU Technology Transfer AS has established 73 spin-off companies, many of which are focused on HealthTech and MedTech. These organisations provide the legal, commercial and financial expertise required to move research from the laboratory to the market.

TTO / Incubator	Core Metric (2024-2025)	Key Outcome	Source
Inven2	116 New Inventions; NOK 670M raised	Transition of researchers to entrepreneurs	Various
NTNU TTO	73 Spin-off companies to date	Scaling academic IP into MedTech firms	Various
Aleap	>18 Alumni; $19M Capital raised	Norway's largest health startup incubator	Various
Norway Health Tech	308 Members; 38 International activities	National driver of public-private collaboration	Various

Collaborative Test Environments: The Smart Care Lab

The "Smart Care Lab," a service provided by Norway Health Tech, allows companies like DNV Imatis and Dignio to document the clinical and operational benefits of their solutions in real-world municipal settings.

This independent validation is crucial for overcoming the "challenges of the Norwegian market," where high-quality standards can sometimes slow down the adoption of new technologies. For example, DNV Imatis demonstrated time savings of 390 hours annually in a single municipality, providing the "hard data" required for larger-scale implementation.

Market Trends and the Future of Norwegian Health Innovation

The Norwegian HealthTech and MedTech sectors are characterised by several emerging trends that will define the next decade of growth.

1. Capital Concentration and Global Integration

Global venture capital data from 2024-2025 indicates a shift toward fewer but larger funding rounds. While overall deal counts are lower than historical averages, the average financing round in the MedTech sector reached $36 Million in the first half of 2025. This "capital concentration" favors mature startups and AI-native firms that can demonstrate clear clinical value and a path to international scaling.

2. The Rise of "HealthFjords" as a Regional Brand

Western Norway, centered around Bergen, has launched the "HealthFjords" identity to position the region as an international powerhouse for health technology. This initiative, supported by the Eitri Innovation Centre and major grants from Agenda Vestlandet, emphasises "human scale" innovation—small enough to be agile, but large enough to lead in diagnostics and digital patient pathways.

3. Sustainability and Social Impact

There is an increasing focus on the "sustainability" of healthcare systems. Leaders like Hege Hansen (Induvita) and Saeid Hosseini (Vilje Bionics) are not just focused on profitability but on creating a more "dignified" and "accessible" healthcare experience.

This alignment with Nordic values, trust, equality and sustainability, is viewed as a competitive advantage in international markets where health equity is becoming a priority.

Conclusion

The future leaders of Norwegian HealthTech and MedTech are distinguished by their ability to combine deep clinical research with sophisticated engineering and AI integration. From Jasper Kurth’s industrialisation of medical isotopes at Thor Medical to Cathrine Ro Heuch’s decentralised migraine care at Nordic Brain Tech, these innovators are solving some of the most complex problems in modern medicine.

The success of these individuals is supported by a robust national strategy that prioritises public-private collaboration, internationalisation, and the documentation of real-world clinical benefits. As Norway continues to transition its economy, the HealthTech and MedTech sectors represent a significant pillar of future growth, capable of delivering both economic value and profound improvements in patient lives worldwide.

The transition from "garage startups" to "global leaders" is well underway, secured by a unique ecosystem that balances Nordic values with international commercial ambition.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech